Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SNOA 
Sonoma Pharmaceuticals Inc (SNOA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: SNOA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14.8
1 Year Target Price $14.8
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.93% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.49M USD | Price to earnings Ratio - | 1Y Target Price 14.8 |
Price to earnings Ratio - | 1Y Target Price 14.8 | ||
Volume (30-day avg) 1 | Beta 1.26 | 52 Weeks Range 1.75 - 6.92 | Updated Date 08/29/2025 |
52 Weeks Range 1.75 - 6.92 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.21 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When After Market | Estimate -0.51 | Actual -0.4793 |
Profitability
Profit Margin -23.84% | Operating Margin (TTM) -27.27% |
Management Effectiveness
Return on Assets (TTM) -16.06% | Return on Equity (TTM) -78.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 4563288 | Price to Sales(TTM) 0.5 |
Enterprise Value 4563288 | Price to Sales(TTM) 0.5 | ||
Enterprise Value to Revenue 0.31 | Enterprise Value to EBITDA -0.17 | Shares Outstanding 1643260 | Shares Floating 1622330 |
Shares Outstanding 1643260 | Shares Floating 1622330 | ||
Percent Insiders 1.23 | Percent Institutions 6.31 |
Upturn AI SWOT
Sonoma Pharmaceuticals Inc
Company Overview
History and Background
Sonoma Pharmaceuticals, Inc. (formerly Oculus Innovative Sciences) was founded in 2005. It focuses on developing and marketing stabilized hypochlorous acid (HOCl) products for various applications, including wound care, eye care, and dermatology. The company has evolved from its initial focus on disinfection to a broader range of therapeutic applications.
Core Business Areas
- Human Healthcare: Development, manufacturing, and marketing of prescription and over-the-counter products for advanced tissue care, primarily using Microcyn Technology (stabilized HOCl). This includes products for wound care, scar management, eye care, and dermatology.
- Animal Healthcare: Products based on Microcyn Technology for use in the veterinary market, treating wounds and other skin conditions in animals.
- International Partnerships: Partnering with distributors and companies to sell Sonoma's products internationally, expanding market reach beyond North America.
Leadership and Structure
The leadership team includes Amy Trombly (CEO), James Schutz (CFO), and other executives managing different areas of the business. The organizational structure is typical for a publicly traded pharmaceutical company with departments for R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Microcyn Technology: Sonoma's core technology platform is based on stabilized hypochlorous acid (HOCl). It is used in various products for wound care, scar management, eye care, and dermatology. Market share data specifically for Microcyn is not readily available. Competitors in wound care include companies like Smith & Nephew (SNN), Mu00f6lnlycke Health Care, and 3M (MMM). Competitors in scar management include companies like Merz Pharma and Cynosure (CCXX).
- OCuSOFT Products: Sonoma distributes OCuSOFT products. Market share is not readily available. Competitors in this space are Johnson & Johnson (JNJ) and Alcon (ALC).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with continuous innovation and development of new therapies. Specific to wound care, scar management, and dermatology, the markets are driven by aging populations, increased incidence of chronic diseases, and rising demand for cosmetic procedures.
Positioning
Sonoma Pharmaceuticals is a niche player in the pharmaceutical industry, focusing on HOCl technology. Its competitive advantage lies in its patented technology and its efficacy in wound care and other applications.
Total Addressable Market (TAM)
The global wound care market is expected to reach hundreds of billions of USD. Sonoma's TAM is smaller, focusing on specific segments within this market. Their positioning centers on specialized areas, allowing them to capture a piece of a larger market.
Upturn SWOT Analysis
Strengths
- Proprietary Microcyn Technology
- Established distribution network
- Multiple product applications (wound care, eye care, dermatology)
- Regulatory approvals for key products
Weaknesses
- Limited financial resources compared to larger competitors
- Dependence on key partnerships for distribution
- Smaller market share in highly competitive markets
- Limited brand recognition compared to established players
Opportunities
- Expansion into new markets (geographically or product categories)
- Increased adoption of HOCl-based therapies
- Strategic partnerships with larger pharmaceutical companies
- Development of new formulations and delivery systems for Microcyn Technology
Threats
- Competition from established players with greater resources
- Regulatory changes and reimbursement pressures
- Patent expiration and generic competition
- Potential for adverse events or safety concerns related to products
Competitors and Market Share
Key Competitors
- Smith & Nephew (SNN)
- Mu00f6lnlycke Health Care
- 3M (MMM)
- Johnson & Johnson (JNJ)
- Alcon (ALC)
Competitive Landscape
Sonoma Pharmaceuticals faces strong competition from larger, more established players. Its advantages lie in its proprietary technology and focus on niche markets, but its weaknesses include limited resources and brand recognition.
Growth Trajectory and Initiatives
Historical Growth: The company's historical growth has been inconsistent, with periods of rapid growth followed by periods of stagnation. This is attributed to the company's inability to maintain its market presence due to large competitors and financial constraints.
Future Projections: Future projections are difficult to make without access to the latest information.
Recent Initiatives: Without sufficient financial data, it is not possible to provide the most recent activities.
Summary
Sonoma Pharmaceuticals is a small player in a competitive pharmaceutical industry. Its Microcyn Technology offers potential advantages, but the company faces financial challenges and strong competition. Future success depends on its ability to expand into new markets and form strategic partnerships. The company is currently delisted, which makes it difficult to assess their viability and future.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Previous financial reports (last available)
- Industry reports (wound care, dermatology)
- Market research reports
- Various news and press releases
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share data is approximate and based on available information. Investing in Sonoma Pharmaceuticals (SNOA) is highly speculative, considering that it is currently delisted.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sonoma Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Boulder, CO, United States | ||
IPO Launch date 2007-01-25 | CEO, President & Director Ms. Amy M. Trombly Esq., J.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 8 | Website https://sonomapharma.com |
Full time employees 8 | Website https://sonomapharma.com | ||
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.